IP Library Patent Application 16157209
Patent Application
App. No. 16/157,209

Peroxide Contact Lens Care Solution

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/157,209
Filed
Oct 11, 2018
Examiner
HIRT, ERIN E
Art Unit
1616
USPC
424/616
Abstract

The invention is directed to a method of cleaning and disinfecting a contact lens. The method includes instructing a consumer to disinfect their contact lens comprising the following steps: remove a contact from an eye and position the lens in a lens assembly that includes a cap member; add a disinfection solution to the lens case such that the lens is submerged in the solution upon closure of the lens case with the cap member. The disinfection solution will comprise 0.5 wt. % to 6 wt. % hydrogen peroxide or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound. The presence of the P-metal modulating compound in the disinfection solution decreases the neutralization rate of the hydrogen peroxide. The disinfection system exhibits a pseudo first-order, half-life of hydrogen peroxide from 12 minutes to 30 minutes over an initial sixty minutes of neutralization following exposure of the disinfection solution to a catalyst comprising a P-metal. This reduction in rate of peroxide neutralization can provide a more effective solution for killing certain microorganisms and fungi.

Claims (25)

1 . A method of cleaning and disinfecting a contact lens, the method comprising instructing a consumer to disinfect their contact lens comprising the following steps:

remove a contact from an eye and position the lens in a lens assembly that includes a cap member;

add a disinfection solution to a lens case such that the lens is submerged in the solution upon closure of the lens case with the cap member, said disinfection solution comprising 0.5 wt. % to 6 wt. % hydrogen peroxide or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound, wherein the solution exhibits a pseudo first-order, half-life of hydrogen peroxide from 12 minutes to 30 minutes over an initial sixty minutes of neutralization following exposure of the disinfection solution to a catalyst comprising a P-metal.

2 . The method of claim 1 wherein upon closure of the lens case with the cap member the disinfection solution exhibits a pseudo first-order, half-life of hydrogen peroxide over the initial sixty minutes of from 14 minutes to 22 minutes, and the concentration of hydrogen peroxide after six hours of neutralization is less than 150 ppm.

3 . A method of cleaning and disinfecting a contact lens, the method comprising instructing a consumer to disinfect their contact lens comprising the following steps:

remove a contact from an eye and position the lens in a lens assembly that includes a cap member;

add a disinfection solution to a lens case such that the lens is submerged in the solution upon closure of the lens case with the cap member, said disinfection solution comprising 0.5 wt. % to 6 wt. % hydrogen peroxide or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound, wherein upon closure of the lens case the solution exhibits a pseudo first-order, half-life of hydrogen peroxide over an initial sixty minutes of neutralization following exposure of the disinfection solution to a catalyst comprising a P-metal, said neutralization is 1.25 times to 2 times greater with the P-metal modulating compound in the solution than in the absence of the P-metal modulating compound.

4 . A method of cleaning and disinfecting a contact lens, the method comprising instructing a consumer to disinfect their contact lens comprising the following steps:

remove a contact from an eye and position the lens in a lens assembly that includes a cap member;

add a disinfection solution to a lens case such that the lens is submerged in the solution upon closure of the lens case with the cap member, said disinfection solution comprising 0.5 wt. % to 6 wt. % hydrogen peroxide or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound, wherein the disinfection solution exhibits a hydrogen peroxide neutralization profile that is more effective against Candida albicans or Serratia marcescens by 0.5 log-kill or greater after an initial four hours of neutralization following exposure of the disinfection solution to a catalyst comprising a P-metal than an equivalent contact lens disinfection solution but without the P-metal modulating compound, said disinfection solution having an osmolality value of from 150 mOsmol/kg to 500 mOsmol/kg following neutralization of the hydrogen peroxide.

5 . The method of claim 1 wherein the P-metal modulating compound is of general formula I

wherein R 1 is C 1 -C 6 alkyl, —(CH 2 ) n CH( + NH 3 )(CO 2 − ) and n is 1 or 2, or NHR 3 ; and R 3 is H or R 2 , and R 2 is H, OH or C 1 -C 6 alkyl.

6 . The method of claim 1 wherein the P-metal modulating compound comprises one or two nitrogen atoms and one to six carbon atoms.

7 . The method of claim 1 wherein the molar ratio of the hydrogen peroxide to the P-metal modulating compound is from 3:1 to 100:1.

8 . The method of claim 3 wherein the P-metal modulating compound is of general formula I

wherein R 1 is C 1 -C 6 alkyl, —(CH 2 ) n CH( + NH 3 )(CO 2 − ) and n is 1 or 2, or NHR 3 ; and R 3 is H or R 2 , and R 2 is H, OH or C 1 -C 6 alkyl.

9 . The method of claim 3 wherein the P-metal modulating compound comprises one or two nitrogen atoms and one to six carbon atoms.

10 . The method of claim 4 wherein the P-metal modulating compound is of general formula I

wherein R 1 is C 1 -C 6 alkyl, —(CH 2 ) n CH( + NH 3 )(CO 2 − ) and n is 1 or 2, or NHR 3 ; and R 3 is H or R 2 , and R 2 is H, OH or C 1 -C 6 alkyl.

11 . The method of claim 4 wherein the P-metal modulating compound comprises one or two nitrogen atoms and one to six carbon atoms.

12 . The method of claim 1 wherein the P-metal modulating compound is an amino acid or a compound derived from an amino acid.

13 . The method of claim 12 wherein the amino acid is present in the solution from 0.05 wt. % to 0.4 wt. %.

14 . The method of claim 1 wherein the disinfection solution further comprises a low foam surfactant, particularly a polyoxyethylene/polyoxypropylene condensation polymer selected from the group consisting of Pluronic® L42, Pluronic® L43, Pluronic® L61, Pluronic® L81, Pluronic® 31R1, Pluronic® 31R2, Pluronic® 25R1, Pluronic® 1781, Pluronic® 17R2, Pluronic® 12R3 and Pluronic® 17R4.

15 . The method of claim 3 wherein the disinfection solution further comprises a low foam surfactant, particularly a polyoxyethylene/polyoxypropylene condensation polymer selected from the group consisting of Pluronic® L42, Pluronic® L43, Pluronic® L61, Pluronic® L81, Pluronic® 31R1, Pluronic® 31R2, Pluronic® 25R1, Pluronic® 17R1, Pluronic® 17R2, Pluronic® 12R3 and Pluronic® 17R4.

16 . The method of claim 4 wherein the disinfection solution further comprises a low foam surfactant, particularly a polyoxyethylene/polyoxypropylene condensation polymer selected from the group consisting of Pluronic® L42, Pluronic® L43, Pluronic® L61, Pluronic® L81, Pluronic® 31R1, Pluronic® 31R2, Pluronic® 25R1, Pluronic® 17R1, Pluronic® 17R2, Pluronic® 12R3 and Pluronic® 17R4.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048715/0432) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061849/0512 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 048715/0406) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061775/0290 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 27, 2019
From: BAUSCH & LOMB INCORPORATED; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; HUMAX PHARMACEUTICAL S.A.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048715/0432 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 27, 2019
From: BAUSCH & LOMB INCORPORATED; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; HUMAX PHARMACEUTICAL S.A.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 048715/0406 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →